FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1151 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Fruquintinib May 13, 2024 No OS Benefit for Active Maintenance Treatment with Olaparib Relative to... July 22, 2022 Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’ March 16, 2021 Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active... August 9, 2022 Load more HOT NEWS MAP Congress 2020: Molecular Analysis for Precision Oncology Seven Ways an Occupational Therapist Can Help Patients Recovering From Breast... The right combination for early detection Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic...
